A Phase I Trial of Simmitinib in Advanced Solid Tumors
Primary Purpose
Advanced Solid Tumor
Status
Recruiting
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
Simmitinib
Sponsored by

About this trial
This is an interventional treatment trial for Advanced Solid Tumor
Eligibility Criteria
Inclusion Criteria:
- Voluntary written informed consent of the patient obtained before any study-specific procedure;
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1;
- Patients with histologically/cytologically confirmed diagnosis of advanced solid tumors refractory to standard therapy or for whom no standard therapy exist;
- Adequate washing period from last anti-tumor therapy;
- Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1;
- The expected survival time for more than 12 weeks;
- Adequate bone marrow, hepatic, renal, pancreas, and coagulation function, Blood phosphorus and calcium in the normal range.
Exclusion Criteria:
- Prior treatment with selective FGFR inhibitors or multi-target kinase Inhibitors with FGFR as the main target;
- Unrecovered from any drug-related adverse event to grade ≤ 1 according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v.3.0 derived from any previous anti-tumor treatment, excluding alopecia, Pigmentation, or other toxicity with little safety risk for subjects;
- Active Central Nervous System (CNS) metastases (brain or leptomeningeal metastases, etc.);
- Any other history of malignancy within 3 years;
- Congenital coagulation abnormalities. Active bleeding or previous history of massive bleeding (>30ml within 3 months), history of hemoptysis (more than 5ml fresh bleeding within 4 weeks);
- Corneal diseases of clinical significance. There is a history of retinal pigment epithelial detachment or evidence of the presence of retinal pigment epithelial detachment. History of age-related macular degeneration or evidence of age-related macular degeneration exists;
- Subjects with impaired cardiac function or heart disease of clinical significance;
- Pregnant or lactating women.
Sites / Locations
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Recruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Simmitinib tablet
Arm Description
The core trial period includes 4-weeks Screening stage (28d), 7-days single administration stage, 4-weeks multiple administration stage (28d), 3-days blood collection stage of PK after multiple administration. The starting dose was set at 1mg/d on toxicology data. Dosing will continue uninterrupted for 28 days in multiple administration stage. The dose-limiting toxicity (DLT) period assessment will be from the first administration of Simmitinib tablet to the end of the first cycle (35 days).
Outcomes
Primary Outcome Measures
Dose-limited toxicity (DLT)
To identify the dose-limited toxicity (DLT).
Maximum tolerated dose (MTD)
To identify the maximum tolerated dose (MTD).
Recommended Phase II Dose (RP2D)
To identify the Recommended Phase II Dose (RP2D).
Secondary Outcome Measures
Area under the plasma concentration versus time curve (AUC)
To preliminarily evaluate the AUC in patients with advanced solid tumors.
Peak Plasma Concentration (Cmax)
To preliminarily evaluate Cmax in patients with advanced solid tumors.
Time of peak plasma concentration (Tmax)
To preliminarily evaluate Tmax in patients with advanced solid tumors.
Overall response rate (ORR)
To preliminarily evaluate ORR in patients with advanced solid tumors.
Duration of Response (DoR)
To preliminarily evaluate DoR in patients with advanced solid tumors.
Median progression free survival (PFS)
To preliminarily evaluate PFS in patients with advanced solid tumors.
Median overall survival (OS)
To preliminarily evaluate OS in patients with advanced solid tumors.
Gene status
FGFR1-4, VEGFA, CSF1, CSF1R and other related gene status
Full Information
NCT ID
NCT04058587
First Posted
August 6, 2019
Last Updated
June 2, 2022
Sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Collaborators
Shanghai Runshi Pharmaceutical Technology Co., Ltd
1. Study Identification
Unique Protocol Identification Number
NCT04058587
Brief Title
A Phase I Trial of Simmitinib in Advanced Solid Tumors
Official Title
Phase I Dose-escalation Trial of Simmitinib for Patients With Advanced Solid Tumors in Therapeutic Failure
Study Type
Interventional
2. Study Status
Record Verification Date
June 2022
Overall Recruitment Status
Recruiting
Study Start Date
June 8, 2020 (Actual)
Primary Completion Date
January 31, 2023 (Anticipated)
Study Completion Date
March 31, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Collaborators
Shanghai Runshi Pharmaceutical Technology Co., Ltd
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
This is an open label, multi-center, phase I study of oral Simmitinib in subjects with advanced solid tumors including gastric cancer.
Detailed Description
This is an open label, multi-center, phase I study of oral Simmitinib in subjects with advanced solid tumors including gastric cancer [including gastroesophageal cancer], cholangiocarcinoma, lung squamous cell carcinoma, urothelial transitional cell carcinoma, and estrogen-receptor-positive breast cancer patients [ER+], etc. This phase I study will evaluate the safety, tolerability, pharmacokinetics and the preliminary efficacy of the FGFR/KDR/CSF1R multi-target inhibitor Simmitinib.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Advanced Solid Tumor
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
50 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Simmitinib tablet
Arm Type
Experimental
Arm Description
The core trial period includes 4-weeks Screening stage (28d), 7-days single administration stage, 4-weeks multiple administration stage (28d), 3-days blood collection stage of PK after multiple administration.
The starting dose was set at 1mg/d on toxicology data. Dosing will continue uninterrupted for 28 days in multiple administration stage.
The dose-limiting toxicity (DLT) period assessment will be from the first administration of Simmitinib tablet to the end of the first cycle (35 days).
Intervention Type
Drug
Intervention Name(s)
Simmitinib
Other Intervention Name(s)
SOMCL-15-290
Intervention Description
The core trial period includes 4-weeks Screening stage (28d), 7-days single administration stage, 4-weeks multiple administration stage (28d), 3-days blood collection stage of PK after multiple administration.
The starting dose was set at 1mg/d on toxicology data. Dosing will continue uninterrupted for 28 days in multiple administration stage.
The dose-limiting toxicity (DLT) period assessment will be from the first administration of Simmitinib tablet to the end of the first cycle (35 days).
Primary Outcome Measure Information:
Title
Dose-limited toxicity (DLT)
Description
To identify the dose-limited toxicity (DLT).
Time Frame
1 year
Title
Maximum tolerated dose (MTD)
Description
To identify the maximum tolerated dose (MTD).
Time Frame
1 year
Title
Recommended Phase II Dose (RP2D)
Description
To identify the Recommended Phase II Dose (RP2D).
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Area under the plasma concentration versus time curve (AUC)
Description
To preliminarily evaluate the AUC in patients with advanced solid tumors.
Time Frame
2 year
Title
Peak Plasma Concentration (Cmax)
Description
To preliminarily evaluate Cmax in patients with advanced solid tumors.
Time Frame
2 year
Title
Time of peak plasma concentration (Tmax)
Description
To preliminarily evaluate Tmax in patients with advanced solid tumors.
Time Frame
2 year
Title
Overall response rate (ORR)
Description
To preliminarily evaluate ORR in patients with advanced solid tumors.
Time Frame
2 year
Title
Duration of Response (DoR)
Description
To preliminarily evaluate DoR in patients with advanced solid tumors.
Time Frame
2 year
Title
Median progression free survival (PFS)
Description
To preliminarily evaluate PFS in patients with advanced solid tumors.
Time Frame
2 year
Title
Median overall survival (OS)
Description
To preliminarily evaluate OS in patients with advanced solid tumors.
Time Frame
2 year
Title
Gene status
Description
FGFR1-4, VEGFA, CSF1, CSF1R and other related gene status
Time Frame
2 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Voluntary written informed consent of the patient obtained before any study-specific procedure;
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1;
Patients with histologically/cytologically confirmed diagnosis of advanced solid tumors refractory to standard therapy or for whom no standard therapy exist;
Adequate washing period from last anti-tumor therapy;
Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1;
The expected survival time for more than 12 weeks;
Adequate bone marrow, hepatic, renal, pancreas, and coagulation function, Blood phosphorus and calcium in the normal range.
Exclusion Criteria:
Prior treatment with selective FGFR inhibitors or multi-target kinase Inhibitors with FGFR as the main target;
Unrecovered from any drug-related adverse event to grade ≤ 1 according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v.3.0 derived from any previous anti-tumor treatment, excluding alopecia, Pigmentation, or other toxicity with little safety risk for subjects;
Active Central Nervous System (CNS) metastases (brain or leptomeningeal metastases, etc.);
Any other history of malignancy within 3 years;
Congenital coagulation abnormalities. Active bleeding or previous history of massive bleeding (>30ml within 3 months), history of hemoptysis (more than 5ml fresh bleeding within 4 weeks);
Corneal diseases of clinical significance. There is a history of retinal pigment epithelial detachment or evidence of the presence of retinal pigment epithelial detachment. History of age-related macular degeneration or evidence of age-related macular degeneration exists;
Subjects with impaired cardiac function or heart disease of clinical significance;
Pregnant or lactating women.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Wen Xu
Phone
0311-67808817
Email
xuwen@cspc.cn
First Name & Middle Initial & Last Name or Official Title & Degree
Xiaowen Liu
Phone
0311-67808817
Email
liuxiaowen@cspc.cn
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yuankai Shi
Organizational Affiliation
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Official's Role
Principal Investigator
Facility Information:
Facility Name
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
City
Beijing
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Wen Xu
Phone
0311-67808817
Email
xuwen@cspc.cn
First Name & Middle Initial & Last Name & Degree
Xiaowen Liu
Phone
0311-67808817
Email
liuxiaowen@cspc.cn
12. IPD Sharing Statement
Learn more about this trial
A Phase I Trial of Simmitinib in Advanced Solid Tumors
We'll reach out to this number within 24 hrs